Reata Pharmaceuticals Inc logo

Reata Pharmaceuticals Inc Share Price Today (NASDAQ: RETA)

Reata Pharmaceuticals Inc share price is $0 & ₹0.00 as on 24 Sep 2023 IST

-172.36

(-100%)

Market is closed - opens 7 PM, 07 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 25 Sep 2023

View live Reata Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Reata Pharmaceuticals Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Reata Pharmaceuticals Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Reata Pharmaceuticals Inc (RETA) Key Statistics

in dollars & INR

Previous Close
$172.36
Open
$172.34
Market Capitalization
$6.6B
Today's Volume
$2.0M
Revenue TTM
$23.5M
EBITDA
$-340.5M
Earnings Per Share (EPS)
$-2.62
Dividend Yield
0.0%
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-112.39%

How to invest in Reata Pharmaceuticals Inc Stock (RETA) from India?

It is very easy for Indian residents to invest directly in Reata Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Reata Pharmaceuticals Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Reata Pharmaceuticals Inc or RETA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Reata Pharmaceuticals Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Reata Pharmaceuticals Inc shares which would translate to null fractional shares of Reata Pharmaceuticals Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Reata Pharmaceuticals Inc, in just a few clicks!

Global Institutional Holdings in Reata Pharmaceuticals Inc

  • Cpmg Inc

    7.60%

  • Vanguard Group Inc

    7.41%

  • BlackRock Inc

    6.66%

  • Adage Capital Partners Gp LLC

    4.64%

  • Deutsche Bank AG

    3.90%

  • Wellington Management Company LLP

    3.86%

Analyst Recommendation on Reata Pharmaceuticals Inc

Rating
Trend

Hold

    37%Buy

    62%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Reata Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

About Reata Pharmaceuticals Inc

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Organization
Reata Pharmaceuticals Inc
Employees
321
CEO
Mr. J. Warren Huff
Industry
Health Technology

Important FAQs about investing in RETA Stock from India :

Can Indians buy Reata Pharmaceuticals Inc shares?

Yes, Indians can invest in the Reata Pharmaceuticals Inc (RETA) from India.

With INDmoney, you can buy Reata Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Reata Pharmaceuticals Inc at zero transaction cost.

How can I buy Reata Pharmaceuticals Inc shares from India?

It is very easy to buy Reata Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Reata Pharmaceuticals Inc (RETA) be purchased?

Yes, you can buy fractional shares of Reata Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Reata Pharmaceuticals Inc stocks?

To start investing in Reata Pharmaceuticals Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Reata Pharmaceuticals Inc?

Today's market capitalisation of Reata Pharmaceuticals Inc RETA is 6.6B

Who is the Chief Executive Officer (CEO) of Reata Pharmaceuticals Inc ?

Mr. J. Warren Huff is the current Chief Executive Officer (CEO) of Reata Pharmaceuticals Inc.